Rubicon Genomics Adds Distributors In China And Licenses IP From University Of Michigan To Enable Next Wave Of Innovation In DNA Library Preparation

--New Agreements Ensure Breadth of Coverage in China and Access to Wide Range of Customers for Rubicon's Leading DNA Library Prep Kits--

--University of Michigan License Will Enable Rubicon's Ongoing Drive to Fundamentally Improve Next Generation Sequencing Libraries--

May 07, 2014, 07:30 ET from Rubicon Genomics, Inc.

ANN ARBOR, Mich., May 7, 2014 /PRNewswire/ -- Rubicon Genomics, Inc., today announced that it has partnered with three life sciences distributors in China to expand availability of its DNA library preparation products, including its ThruPLEX®-FD Prep Kits and PicoPLEX™ DNA-seq Kits for use with Illumina® next-generation sequencing (NGS) systems. The Chinese distributors include EMTD (Beijing Emei Tongde Technology Development Co. Ltd), RockGene BioTech Ltd. and GeneOcean (Wuhan) Biotech Ltd.  All three specialize in the sale and servicing of advanced genetic tools and consumables for life sciences and diagnostic applications.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, "China is rapidly becoming one of the most important markets in the world for advanced life science and biomedical products. To ensure wide coverage of our ThruPLEX and PicoPLEX products countrywide, we have enlisted three leading Chinese distributors with strong records of sales and technical support. We look forward to China becoming an important source of sales for Rubicon."

Separately, Rubicon announced that it has obtained a license for certain intellectual property (IP) owned by the University of Michigan. Rubicon has embarked on a major development project to further advance its leading technology for DNA library preparation, and the newly-licensed IP will enable that effort.

Dr. Koziarz added, "We view our current DNA library preparation technology as 'best in class,' but we also are convinced that we can do better yet. Our researchers are developing technologies that we believe have the potential to fundamentally improve current approaches to DNA library preparation, and the intellectual property we have licensed from the University of Michigan could be an important element in this effort."

ThruPLEX-FD Prep Kits streamline library preparation for fragmented DNA/cDNA and reduce sample input amounts to picogram levels. ThruPLEX-FD's patented technology delivers a highly-efficient and user-friendly process that takes place in a single tube in less than two hours, improves ligation efficiency and eliminates clean-up steps. ThruPLEX-FD provides accurate and reproducible results for applications including DNA-seq, RNA-seq and ChIP-seq, and is especially effective for clinical samples such as plasma and FFPE.

PicoPLEX WGA and PicoPLEX DNA-seq Kits amplify DNA from a single cell into highly accurate and reproducible DNA libraries. The product has been used by leaders in the IVF market for pre-implantation genetic screening of embryos to identify aneuploidy and copy number variation on microarrays and Illumina NGS platforms. PicoPLEX's patented technology is optimized for amplification of single copy genomic DNA with input amounts of less than six picograms. The easy-to-use single tube protocol reduces handling errors and background and dramatically improves time to results. 

Click here for more information on Rubicon's distributors.

About Rubicon Genomics  
Rubicon Genomics, Inc. is a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing on NGS, microarray and q-PCR platforms. The company creates efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult samples to facilitate gene-based research, drug development and diagnostics.  Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit



Rubicon Genomics

Barbara Lindheim

Jamie Wibbenmeyer, PhD

BLL Partners, LLC

Business Development

(212) 584-2276

SOURCE Rubicon Genomics, Inc.